What is GenoFAB?
GenoFAB, formerly GenoCAD, specializes in the provision of a comprehensive catalog of plasmids, essential for a wide range of scientific applications. Their offerings include both classic and innovative plasmid designs, such as TrueVectors, engineered for enhanced scalability and security. The company caters to scientists involved in routine experimental work, advanced gene therapies, and large-scale biomanufacturing.
Services encompass plasmid design, synthesis, purification, and distribution, all aimed at enhancing research efficiency and fostering innovation within the biotechnology and synthetic biology fields. Founded in 2019 and based in Fort Collins, Colorado, GenoFAB is committed to delivering reliable plasmid solutions to the scientific community.
How much funding has GenoFAB raised?
GenoFAB has raised a total of $30K across 1 funding round:
Debt
$30K
Debt (2021): $30K with participation from PPP
What's next for GenoFAB?
With the recent substantial expansion capital, GenoFAB is poised for significant operational scaling and market expansion. The company's strategic focus on supporting gene therapy and biomanufacturing indicates a clear path toward becoming a key player in the synthetic biology ecosystem.
Future developments are expected to include enhancements in plasmid synthesis capabilities and broader distribution networks, further solidifying their role in advancing scientific discovery and therapeutic development. The investment will likely fuel research and development into novel plasmid technologies and streamline production processes to meet growing industry demand.
